hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06276530 id: APHP231036 briefTitle: Impact of Surgical Approach on Adaptation of Posture-respiratory Coupling acronym: VaPosVent overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-02 date: 2025-03 date: 2024-02-26 date: 2024-02-26 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: This study aims to identify physiopathologic mechanisms related to surgical approaches during lobectomies for non-small cell lung cancer which can explain the better quality of life and the decrease of of post-operative complications in minimally invasive techniques (video-assisted thoracic surgery and robotic-assisted thoracic surgery) compared to conventional thoracotomy. conditions: Resectable Lung Non-Small Cell Carcinoma studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 50 type: ESTIMATED name: EOS imaging for musculoskeletal disorder name: Movement analysis by an optoelectronic camera. name: Stabilometric measurement by strength platform measure: Thoracic kyphosis (T1- T12 angle) and vertical alignment head-pelvis and head- C7 vertebra (angle OD-HA and OD-C7) (EOS) measure: Width of rib cage (EOS) measure: Rib cage volume (EOS) measure: " Umbrella "angle (EOS) measure: Center of Pressure displacement (Optoelectronic system) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Thoracic and Vascular Surgery Tenon University Hospital city: Paris zip: 75020 country: France name: Harry ETIENNE, M.D., PhD role: CONTACT phone: +33 6 67 96 82 89 email: h.etienne@hotmail.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06276517 id: APHP220918 id: 2022-A01739-34 type: OTHER domain: IDRCB briefTitle: Hidden Impairments During Subarachnoid Haemorrhage Recovery, Description and Evolution of a Newly Described Syndrom acronym: HIDDEN overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2028-03 date: 2028-03 date: 2024-02-26 date: 2024-02-26 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Descriptive observational study in patients with spontaneous subarachnoid hemorrhage or following aneurysmal rupture to assess the presence of a post-HSA syndrome at 3 months, 6 months and 1 year, and its impact on functional outcome using the Rivermead questionnaire conditions: Intracranial Hemorrhages studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: questionnaire name: SS-QoL name: SF-36 name: CIQ-R name: BREFF name: MoCA name: IADL name: mMRS name: PCL-5 name: Brief-Cope measure: Evaluate the presence of post SAH syndrome at 3 months and its impact on return to work using the Rivermead Post-Concussion symptoms questionnaire (RPQ), and its impact on functional outcome. measure: - study the factors determining the presence of a post-HSA syndrome and an inability to return to work at 3 months, 6 months and 1 year measure: To study the prevalence of post-traumatic stress in this population measure: Study patients' coping strategies in relation to functional recovery using the Brief-Cope self-questionnaire sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06276504 id: APHP211001 id: 2023-503520-31-00 type: OTHER domain: EU CT number briefTitle: Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection acronym: PENALTY overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-04 date: 2028-04 date: 2024-02-26 date: 2024-02-26 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: This study aims to assess the efficacy and safety of pembrolizumab in immunocompromised patients with progressive multifocal leukoencephalopathy (PML). This phase II, multicenter, single-arm study includes patients with an underlying cause of immunosuppression hardly reversible, i.e. not the patients with HIV nor those receiving biologics for chronic inflammatory diseases. Patients will receive intravenous pembrolizumab (2 mg/kg, maximum 200 mg) at month 0, 1 and 2 (total of three doses). The primary endpoint will be achieving at least one negative result of JCV viral load in cerebrospinal fluid (CSF) within the M0 to M3 period. conditions: Progressive Multifocal Leukoencephalopathy studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 33 type: ESTIMATED name: Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection measure: Negativation of JCV viral load in the CSF as assessed by PCR: at least one JCV PCR in the CSF negative in the Day 0 to Month 3 period measure: Negativation of JCV PCR viral load in the CSF: cumulative incidence of negative JCV viral load measures by PCR in CSF, with death as competing event measure: Evolution of the JCV viral load in the CSF (repeated measures JCV PCR in CSF) measure: Repositivation of JCV PCR: at least a positive result following at least a negative result measure: Evolution of National Institutes of Health Stroke Scale (NIHSS) score measure: Evolution of 6-item Modified Rankin Scale score (includes death as most severe state) measure: Evolution of Glasgow Outcome Scale Extended (GOS-E) score measure: Relapse or progression measure: Death (and date of death) measure: Cause specific death: death related to PML measure: Any adverse event classified by using US NCI CTCAE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital Pitié-Salpêtrière - Médecine Intensive Réanimation city: Paris zip: 75013 country: France name: Nicolas WEISS, Pr role: CONTACT phone: +33 (0)1 42 16 27 70 email: nicolas.weiss@aphp.fr lat: 48.85341 lon: 2.3488 facility: Hôpital Pitié-Salpêtrière - Service d'hématologie clinique city: Paris zip: 75013 country: France name: Damien ROOS-WEIL, Dr role: CONTACT phone: +33 (0)1 42 16 15 96 email: damien.roosweil@aphp.fr lat: 48.85341 lon: 2.3488 facility: Hôpital Pitié-Salpêtrière - Service des Maladies infectieuses et tropicales city: Paris zip: 75013 country: France name: Valérie POURCHER, Pr role: CONTACT phone: +33 (0)1 42 16 02 62 email: valerie.martinez@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06276491 id: XmAb541-01 briefTitle: Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors overallStatus: RECRUITING date: 2024-04-04 date: 2027-12 date: 2028-12 date: 2024-02-26 date: 2024-04-18 name: Xencor, Inc. class: INDUSTRY briefSummary: The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate effect of XmAb541 on tumor outcomes. conditions: Ovarian Cancer conditions: Endometrial Cancer conditions: Germ Cell Tumor conditions: Testicular Germ Cell Tumor conditions: Ovarian Germ Cell Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL interventionModelDescription: Dose escalation and expansion study primaryPurpose: TREATMENT masking: NONE count: 212 type: ESTIMATED name: XmAb541 measure: Incidence of Adverse Events measure: Incidence of dose-limiting toxicities (DLTs) measure: Incidence of cytokine release syndrome (CRS) measure: Measurement of Cmax measure: Measurement of area under curve (AUC) measure: Measurement of Ctrough measure: Objective Response Rate measure: Duration of Response measure: Changes in Circulating Tumor DNA (ctDNA) sex: ALL minimumAge: 15 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Montefiore Einstein Comprehensive Cancer Center status: RECRUITING city: Bronx state: New York zip: 10461 country: United States lat: 40.84985 lon: -73.86641 hasResults: False
nctId: NCT06276478 id: 2024-PEDOAI briefTitle: Positive Psychological Deconditioning of Pediatric Patients With Dental Anxiety Through Artificial Intelligence overallStatus: ENROLLING_BY_INVITATION date: 2024-03-04 date: 2024-06 date: 2024-06 date: 2024-02-26 date: 2024-03-07 name: University of Pavia class: OTHER briefSummary: Pediatric patients who will be attending dental treatment at both the Orthodontics and Pediatric Dentistry Unit, Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences at the University of Pavia, Pavia, Italy and a private dental practice in Genoa, Italy, will be recruited for the study.
A cartoon version of a small molar will be drawn using the software Paint (version 22000.0, Microsoft Corporation, Redmond, Washington State, U.S.). The drawing will be animated using an AI-based software (Sketch MetaDemolab, Meta AI Research, Astor Place, New York city, New York, U.S.). A text will be created in collaboration with OpenAI (version 3.5, Open AI, San Francisco, California, U.S.) to be integrated into the video, utilizing terminology deemed most suitable for a patient with dental anxiety. The text will be transformed from written to spoken dialogue using an AI-based software (Flexclip, version 5.6.0, PearlMountain, Hong Kong, China), and then incorporated into the video.
Children will undergo the first dental visit at the baseline (T0), in which the following indexes will be assessed: Modified Dental Anxiety Scale (MDAS), Face-Leg-Activity-Cry-Consolability Scale (FLACC), Simplified Oral Hygiene Index (OHI-S), Bleeding on Probing (BOP) and the International Caries Detection and Assessment System (ICDAS). They will be randomly divided into two group:
At the second visit (T1), scheduled approximately after two weeks, the variables will be re-evaluated and professional debridement will be performed with a piezoelectric instrument (Satelect Acteon Newton p5 xs,Acteon Group, Mèrignac, France and Sonicflex Kavo, KaVo Dental, Biberach an der Riss, Germany) and manual scaler/curettes (Courette 9/10, 11/12 and 13/14 Gracey and Scaler lm 23, Hu Friedy, Europe). Values will be registered again, for the third time, after the professional debridement. conditions: Dental Anxiety conditions: Dental Phobia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 42 type: ESTIMATED name: AI-video name: Verbal instructions measure: Change in Modified Dental Anxiety Scale - MDAS (Humphris GM et al. 1995) measure: Change in Face, Leg, Activity, Cry, Consolability Scale - FLACC (Merkel, S. I. et al., 1997) measure: Change in Bleeding on Probing - BoP (Löe H. et al.,1967) measure: Change in Simplified Oral Hygiene Index - OHI-S (Greene JC et al, 1964) measure: International Caries Detection and Assessment System - ICDAS sex: ALL minimumAge: 4 Years maximumAge: 8 Years stdAges: CHILD facility: Unit of Orthodontics and Pediatric Dentistry - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Pediatrics - University of Pavia city: Pavia state: Lombardy zip: 27100 country: Italy lat: 45.19205 lon: 9.15917 hasResults: False
nctId: NCT06276465 id: UC-GTG-2306 id: 2023-507482-26-00 type: OTHER domain: EU-CT briefTitle: Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging acronym: PEACE8 overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2024-07-01 date: 2032-07-01 date: 2024-02-26 date: 2024-02-26 name: UNICANCER class: OTHER name: Bayer briefSummary: In earlier stages of prostate cancer, male sexual hormones (androgens) stimulate the growth of cancer cells. Castration-resistant prostate cancer (CRPC) means that the prostate cancer continued to grow despite patients are taking hormone therapy to control the disease. One of the standard treatments for these patients is so-called 'new generation' hormonal therapy. These hormone therapies include apalutamide, enzalutamide, or darolutamide. They work by blocking androgen receptors that play an important role in the growth of prostate cancer.
The treatment proposed as part of this research is a combination of oral darolutamide, approved in Europe to treat patients with CRPC who do not have metastasis visible on CT-scan or bone scintigraphy (but visible with positron emission tomography-scan (PET-Scan), a more precise imaging technique) with stereotactic body radiotherapy (SBRT), a new radiotherapy technique guided by very high precision medical imaging. This method makes it possible to better target cancer cells while preserving neighboring healthy organs.
* Experimental arm: ADT + darolutamide + SBRT. primaryPurpose: TREATMENT masking: NONE count: 336 type: ESTIMATED name: Darolutamide 300 mg name: Stereotactic body radiation therapy name: Androgen deprivation therapy measure: Radiographic Progression-free survival (rPFS) measure: Time to treatment failure (TTF) measure: Overall survival (OS) measure: Prostate cancer-specific survival measure: Time to PSA progression measure: Biochemical response rate measure: Time to next symptomatic skeletal event (SSE) measure: Time to pain progression measure: Safety/tolerance measure: Functional Assessment of CAncer Therapy - Prostate (FACT-P) measure: Brief Pain Inventory - Short Form (BP-SFI) questionnaire sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06276452 id: 23.0434 id: U2CDA050097 type: NIH link: https://reporter.nih.gov/quickSearch/U2CDA050097 briefTitle: Supporting Resilience Among Re-entered Seniors acronym: SRRS overallStatus: RECRUITING date: 2024-03-09 date: 2024-11-30 date: 2024-11-30 date: 2024-02-26 date: 2024-03-15 name: University of Louisville class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: The first goal (Aim 1) of this clinical trial is to learn about specific strengths, challenges, and desired areas of knowledge and skill-building among older adults who re-entered their communities from a period of incarceration and to then develop a new psychoeducational intervention tailored to these older adults. The second goal (Aim 2) of this clinical trial is to test if the intervention increases chronic disease management and whether the intervention is considered appropriate and acceptable by older adults who re-entered their communities from a period of incarceration.
* complete three follow up surveys conditions: Chronic Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 8 type: ESTIMATED name: Psychoeducation measure: Chronic disease self managment sex: MALE minimumAge: 45 Years stdAges: ADULT stdAges: OLDER_ADULT facility: New Legacy Reentry status: RECRUITING city: Louisville state: Kentucky zip: 40203 country: United States name: Stephanie Grace Prost, PhD role: CONTACT email: stephanie.prost@louisville.edu lat: 38.25424 lon: -85.75941 hasResults: False
nctId: NCT06276439 id: IRB23-0314 briefTitle: Intraoperative Imaging of Lymph Nodes overallStatus: RECRUITING date: 2024-02-19 date: 2025-03-30 date: 2026-02-19 date: 2024-02-26 date: 2024-02-26 name: University of Illinois at Urbana-Champaign class: OTHER name: U.S. National Science Foundation name: Ss. Cyril and Methodius University of Skopje, Macedonia briefSummary: One-third of the global population battles cancer, with surgery being the primary treatment for localized forms. Successful treatment often hinges on the thorough removal of primary tumors and pinpointing cancerous sentinel lymph nodes (SLN). Although modern surgical imaging and fluorescent probes enhance the detection of sentinel lymph nodes using near-infrared (NIR) fluorescence, their inability to precisely determine the nodes' status can result in additional surgeries, lymphedema, and a reduced quality of life for patients. Our research direction aims to harness the potential of bioinspired imaging technologies with the goal of precisely identifying SLN status and ensuring only the cancerous lymph nodes are excised during the initial procedure. To realize this objective, we're drawing inspiration from the mantis shrimp's visual system to create a single-chip multispectral camera that spans the deep ultraviolet to the near-infrared spectrum. Our pioneering sensor seamlessly combines perovskite nanocrystals, optical filters, and vertically-aligned photodetectors on a single chip, enabling concurrent imaging of external NIR fluorophores and internal UV fluorescence from tumor-specific markers. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 48 type: ESTIMATED name: Surgical removal of breast cancer and lymph nodes measure: Positive lymph node detection with custom sensors sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Clinic Hospital status: RECRUITING city: Skopje zip: 1000 country: North Macedonia name: Viktor Gruev, PhD role: CONTACT phone: +1.267.847.4020 email: vgruev@illinois.edu name: Goran Kondov, MD, PHD role: CONTACT phone: +389 70 252010 email: kondov@yahoo.com lat: 41.99646 lon: 21.43141 hasResults: False
nctId: NCT06276426 id: 24468 briefTitle: Plants Optimizing Development Study (PODS) acronym: PODS overallStatus: RECRUITING date: 2024-03-18 date: 2026-09-30 date: 2026-09-30 date: 2024-02-26 date: 2024-04-17 name: University of Illinois at Urbana-Champaign class: OTHER name: Soy Nutrition Institute briefSummary: This study aims to conduct a randomized clinical trial to measure the effects of a 3-month daily mixed-soy food intervention vs. a control group receiving isocaloric foods on reproductive hormones, body composition, metabolic risk, fecal microbiota, and cognition among 8-11-year-old children. Additionally, this study will assess soy food intake immediately following participation in the clinical trial to determine changes in soy food acceptance in children. conditions: Healthy Children studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 96 type: ESTIMATED name: Soy foods name: Non-Soy Plant-Based Foods measure: Sex steroid excretion measure: Gut microbiota measure: Attentional Accuracy measure: Attentional Reaction Time measure: Hippocampal-dependent Relational memory measure: Body Composition measure: Metabolic Markers measure: Pubertal Staging measure: Cognitive Abilities and Academic Achievement sex: ALL minimumAge: 8 Years maximumAge: 11 Years stdAges: CHILD facility: University of Illinois status: RECRUITING city: Urbana state: Illinois zip: 61801 country: United States name: Naiman Khan, PhD, RD role: CONTACT phone: 217-300-2197 email: nakhan2@illinois.edu name: Naiman Khan, PhD, RD role: PRINCIPAL_INVESTIGATOR lat: 40.11059 lon: -88.20727 hasResults: False
nctId: NCT06276413 id: REBRA id: REBRA type: REGISTRY domain: REBRA briefTitle: REgistRy BRAnch goRE EndopRosthEsis acronym: REBRA overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-12-31 date: 2030-12-31 date: 2024-02-26 date: 2024-02-26 name: University Hospital Padova class: OTHER briefSummary: Multicenter registry on patients treated by the new Gore thoracic branched endoprosthesis conditions: Aortic Aneurysm, Thoracic conditions: Aortic Dissection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: GORE TAG Thoracic Branch Endoprosthesis measure: early mortality measure: device stability measure: technical success measure: early major adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Vascular and Endovascular Clinic - Padova University city: Padova zip: 35020 country: Italy name: Michele Piazza, Pr role: CONTACT phone: 3498644688 email: michele.piazza@unipd.it lat: 45.40797 lon: 11.88586 hasResults: False
nctId: NCT06276400 id: 4-24-0023:1 briefTitle: LPFC Organization in Emotion-Duration Difference Estimation overallStatus: RECRUITING date: 2024-01-29 date: 2028-03-31 date: 2028-03-31 date: 2024-02-26 date: 2024-03-05 name: University of California, Santa Barbara class: OTHER briefSummary: To support optimal behavior in daily life, goals and responses following emotional events should ideally incorporate not only the valence and intensity of prior emotional episodes but also their temporal features, such as the relative duration of positive vs. negative attributes. However, how specific brain regions contribute to the integration of temporal and emotional information and promote goal-directed response remains unknown.
The goal of this study is to examine how specific brain regions track both emotional and temporal information of dynamic emotional events to inform other related brain regions to guide goal-oriented and context-appropriate actions. The investigators will scan healthy human participants using functional MRI (fMRI) while they view emotional image sequences and track the associated emotional and temporal (duration) information, and act accordingly. The investigators will employ multivariate patterns analysis and pattern similarity analysis to identify brain regions that represent (can decode) emotion, time, and their combined signals, as well as brain regions that represent the associated action goal. In addition, to infer the causal contributions of these brain regions in forming task-relevant representations (emotion, time, and action goal), the same participants will be recruited to receive transcranial magnetic stimulation (TMS) in these regions. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a basic science study in which all participants will participate in all task conditions within each experiment (repeated-measures design). primaryPurpose: BASIC_SCIENCE masking: NONE maskingDescription: Participants will typically be unaware of the conditions presented, though because these involve manipulations of stimuli or task demands, they may be aware of the manipulation. This is not expected to impact the primary outcome measures (e.g., BOLD signal activation patterns). count: 50 type: ESTIMATED name: Emotion valence name: Time name: TMS Stimulation measure: Multivariate BOLD metrics measure: Behavioral response sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: University of California, Santa Barbara status: RECRUITING city: Santa Barbara state: California zip: 93106 country: United States lat: 34.42083 lon: -119.69819 hasResults: False
nctId: NCT06276387 id: K23AT011768-01 type: NIH link: https://reporter.nih.gov/quickSearch/K23AT011768-01 id: K23AT011768 type: NIH link: https://reporter.nih.gov/quickSearch/K23AT011768 briefTitle: Defining Stress REsilience And Mindfulness Effects in Rheumatoid Arthritis acronym: DREAMER overallStatus: RECRUITING date: 2024-01-26 date: 2025-12 date: 2025-12 date: 2024-02-26 date: 2024-02-26 name: University of California, San Francisco class: OTHER name: National Center for Complementary and Integrative Health (NCCIH) briefSummary: This clinical trial will test a mindfulness program in individuals with rheumatoid arthritis (RA). The main goals of this pilot study are to: